How to Get Wegovy Covered by Insurance

Step 1: Confirm coverage exists

Log into your insurer's member portal. Search "Wegovy." If listed on the formulary, note the tier (usually specialty). If not listed, look for the drug class "anti-obesity medications" — some plans exclude the whole category regardless of drug.

If your plan explicitly excludes the anti-obesity class, prior authorization won't save you. Skip to the "when you have no coverage" section below.

Step 2: Gather documentation

Have these ready before you see your clinician:

• Height and weight for BMI calculation (BMI ≥30, or ≥27 with comorbidity)
• Comorbidity documentation: ICD-10 codes for hypertension (I10), dyslipidemia (E78.5), type 2 diabetes (E11.9), sleep apnea (G47.33), CV disease
• Prior weight-loss attempts: 3–6 months of documented diet/exercise counseling, structured programs (WW, Noom), or prior medications
• Family history of medullary thyroid carcinoma or MEN 2 (must be negative)
• Pregnancy status (must be negative)

Step 3: The prior authorization

Your clinician submits the PA. Typical language that works:

"Patient has BMI of [X] with documented [comorbidity + ICD code]. Patient has completed a supervised weight-loss attempt for [duration] with insufficient results. Patient has no personal or family history of medullary thyroid carcinoma or MEN 2 syndrome. Requesting semaglutide 2.4 mg per FDA-approved indication for chronic weight management."

Step 4: If denied

1. Read the denial letter. The specific reason (BMI not documented, no comorbidity, missing prior lifestyle attempt) tells you what to add on appeal.
2. File a formal appeal within the deadline (usually 60 days). Include a letter of medical necessity from your clinician addressing each denial reason.
3. Request a peer-to-peer. Your clinician calls the insurance medical director. Many approvals happen here.
4. External review. If internal appeals fail, most states offer an independent external review at no cost. Success rates are ~40% for weight-loss drugs.

The SELECT trial angle

If you have obesity + established cardiovascular disease (prior MI, stroke, or peripheral artery disease), cite the SELECT trial. Wegovy has an FDA indication for CV risk reduction in this population. Framing the appeal around cardiovascular protection rather than weight loss opens coverage on some plans that exclude anti-obesity meds — including Medicare Part D.

Employer-sponsored plans: talk to HR

If your employer's plan excludes anti-obesity medications, HR is the ultimate decision-maker. Some large employers added coverage in 2024–2025. A well-written email to HR benefits, citing SELECT and the health-cost math for cardiovascular events prevented, sometimes moves the needle.

When you have no coverage

• Novo Nordisk savings card: $0 copay for eligible commercially insured patients whose plan covers Wegovy (not helpful if plan doesn't cover)
• NovoCare direct: ~$499/month single-dose vials for uncovered commercial patients
• LillyDirect Zepbound vials: $349–$499/month — the cheapest brand-name path in 2026
• Compounded semaglutide: $150–$400/month, legal only under narrow medical-necessity criteria

Documentation checklist

• Height, weight, BMI
• Comorbidity diagnoses with ICD-10 codes
• Documentation of 3–6 months prior lifestyle attempts
• Labs: A1c, lipid panel, basic metabolic (comfort for insurer)
• Confirmation of no MTC/MEN 2 family history
• Confirmation of not pregnant / birth control if relevant

FAQ